UNSPECIFIED BD? PEN NEEDLE UNKNOWN

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a consumer,other report with the FDA on 2020-03-26 for UNSPECIFIED BD? PEN NEEDLE UNKNOWN manufactured by Becton Dickinson.

Event Text Entries

[185199321] Unknown manufacturer: there are multiple bd locations where this unspecified bd device may have been manufactured. A catalog and lot number could not be confirmed for this incident and without this information we are unable to determine where the device was manufactured. Therefore, bd corporate headquarters in (b)(4) has been listed and the (b)(4) fda registration number has been used for the manufacture report number. Medical device expiration date: unknown. Device manufacture date: unknown. Investigation summary: level a investigation - complaint evaluation / complaint history check for the event(s) that occurred. Severity: s_2__; occurrence: unable to perform complaint lot history check due to an unknown lot number for hyperglycemia. Investigation summary: no samples (including photos) were returned therefore the complaint could not be confirmed and the root cause is undetermined. If samples are received in the future the complaint will be reopened for further investigation. Unable to perform dhr check due to an unknown lot number for hyperglycemia. Investigation conclusion: as no samples and/or photo(s) were received the investigation concluded: unconfirmed: bd was not able to duplicate or confirm the customer? S indicated failure as no samples or photos were returned. Complaints received for this device and reported condition will continue to be tracked and trended. Information will be captured on trend reports and monitored monthly. Our business team regularly reviews the collected data for identification of emerging trends. Root cause description: root cause cannot be determined at this time as the issue is unconfirmed as no samples or photos were returned. Rationale: based on the investigation, no additional investigation and no capa is required at this time.
Patient Sequence No: 1, Text Type: N, H10


[185199322] It was reported that unspecified bd? Pen needle was unable to deliver insulin and caused blood sugar levels to be high. This was discovered during use. The following information was provided by the initial reporter: material no: unknown batch no: unknown. It was reported that the blood sugar levels were high as insulin glargine dose was not administered. Information regarding the outcome of the event, corrective treatment and insulin glargine action taken was not reported. The patient was the operator of the suspect pen, however her training status was not reported. The general model duration of use and the suspect pen duration of use was not reported. The action taken of the suspect pen was not reported and its return was not expected. Verbatim: blood sugar levels were high [blood glucose increased]. The patient did not administer basaglar due to a possible issue with kwikpen device, ns (blood glucose increased) [product dose omission]. Case description: this solicited case, reported by a consumer who was participating in a patient assistance program (pap). Medical history and concomitant medications were not reported. The patient received insulin glargine (basaglar) injections via pre-filled pen (kwikpen). Dosage regimen, route of administration, indication for use and start therapy date were not reported. On (b)(6) 2020, she had an issue with four kwikpens from the same box and lot number as insulin glargine was not being dispensed, due to this, it was believed insulin glargine dose was missed. Bd needles 23gx4mm were used and priming with two units was performed prior every injection. On (b)(6) 2020, blood sugar levels were high as insulin glargine dose was not administered. Information regarding the outcome of the event, corrective treatment and insulin glargine action taken was not reported. The patient was the operator of the suspect pen, however her training status was not reported. The general model duration of use and the suspect pen duration of use was not reported. The action taken of the suspect pen was not reported and its return was not expected. The reporting consumer did not provide causality assessment between the events and insulin glargine but related the events to the suspect kwikpen. Analysis statement: company assessment of relatedness ((b)(6) 2020): the events blood glucose increased and product dose omission are not reasonably possibly related to insulin glargine because blood glucose increased is commonly associated with diabetes mellitus, the approved indication for this drug, and product dose omission is external to drug action.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number2243072-2020-00507
MDR Report Key9887077
Report SourceCONSUMER,OTHER
Date Received2020-03-26
Date of Report2020-03-20
Date of Event2020-02-17
Date Mfgr Received2020-03-19
Date Added to Maude2020-03-26
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Reporter OccupationOTHER HEALTH CARE PROFESSIONAL
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactBDX BRETT WILKO
Manufacturer Street9450 SOUTH STATE STREET
Manufacturer CitySANDY UT 84070
Manufacturer CountryUS
Manufacturer Postal84070
Manufacturer Phone8015652341
Manufacturer G1BECTON DICKINSON
Manufacturer Street1 BECTON DRIVE
Manufacturer CityFRANKLIN LAKES NJ 07417
Manufacturer CountryUS
Manufacturer Postal Code07417
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameUNSPECIFIED BD? PEN NEEDLE
Generic NamePEN NEEDLE
Product CodeFMI
Date Received2020-03-26
Catalog NumberUNKNOWN
Lot NumberUNKNOWN
OperatorLAY USER/PATIENT
Device AvailabilityN
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerBECTON DICKINSON
Manufacturer Address1 BECTON DRIVE FRANKLIN LAKES NJ 07417 US 07417


Patients

Patient NumberTreatmentOutcomeDate
101. Other 2020-03-26

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.